Adagene launches investigator-initiated Phase 2 trial of ADG126 (muzastotug) in combination with KEYTRUDA for stage II/III colorectal cancer patients, with enrollment starting April 2025.
Updated Phase 1b/2 trial data reveals ADG126 combined with pembrolizumab achieved a 33% overall response rate in microsatellite stable colorectal cancer patients, showing improvement from previous 23% response rate.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.